



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

FEB 24 2003

RECEIVED

34/E
D.G.J.
2/25/03

In re application of: Moore et al.

Application Serial No.: 09/376,430

Art Unit: 1646

Filed: August 18, 1999

Examiner: O'Hara, E.

For: **Cytokine Receptor Common
Gamma Chain Like**

Attorney Docket No.: PF466P1

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.114

Box RCE

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated November 19, 2002, (Paper No. 31), wherein a response is due on or before February 19, 2003, Applicants hereby request that the following amendments and remarks be entered into the above-identified application. Submitted concurrently herewith is: (a) a Fee Transmittal; (b) a Request for Continued Examination; and (c) a Version With Markings to Show Changes Made. Please amend the application as follows.

In the Claims:

Please cancel claims 57, 58, 62, 63, 80 and 84.

Please amend claims 40-43, 47-56, 59-61, 64-76, 89, 95 and 100-102 as follows:

40. (Amended Three Times) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:

(a) amino acid residues m to 371 of SEQ ID NO:2, where m is an integer in the range of +1 to +370;

(b) amino acid residues 1 to n of SEQ ID NO:2, where n is an integer in the range of +2 to +371; and

(c) amino acid residues m to n of SEQ ID NO:2, where m is an integer in the range of +1 to +370 and n is an integer in the range of +2 to 371,

E